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A B S T R A C T   
Background: Presently, pills and injections are the two modes of therapeutic treatment available for tuberculosis 
(TB) patients. Many researchers have hypothesized inhalation drug delivery for reducing treatment times and 
possibly limiting the insurgence of drug resistance. This study was aimed at identifying and assessing the 
preferences of inhalation therapy over injections/pills among pulmonary TB patients. 
Method: Cross-sectional study design was used and a sample of 477 participants were recruited at selected three 
Directly Observed Treatment Short-Course (DOTS) centers in Bhiwandi city. Data was collected through self- 
reported questionnaire. Descriptive statistics were reported, and binomial regression models were applied for 
data analysis. 
Results: The preference of inhalants over pills/injections among pulmonary TB patients was significantly asso-
ciated with clinical characteristics. The patients who underwent treatment for more than 1 year were 1.7 times 
more likely to prefer inhalants over pills/injections when compared with treatment duration of less than 1 year. 
Similarly, patients taking five or more pills/day were 1.7 times more likely to prefer inhalants over pills/in-
jections when compared with patients taking 1–4 pills per day. 
Conclusion: The study results signify that inhalants could be an acceptable method of drug delivery in this 
population of TB patients. Diverse drug delivery options for TB patients may greatly contribute towards TB 
treatment adherence.   
1. Introduction 
Due to the global advancement in biomedicine and research, the 
treatment for tuberculosis (TB) is readily available and highly successful 
[1]. However, considering drug resistance and the long duration of 
treatment, TB remains a serious global threat to the mankind. India not 
only shares the highest TB burden in the world accounting for 27% of the 
global TB cases [2], but also shares over a quarter of global burden of 
multi-drug resistant TB (MDR-TB) cases [3,4]. In 2014, the first National 
Anti-Tuberculosis Drug Resistance survey conducted by the Indian 
Government in collaboration with the World Health Organization 
(WHO) and the United States Agency for International Development 
(USAID) showed that, close to 23% of new cases have resistance to any 
drug with MDR-TB being detected in 3% of the cases [5]. Lengthy 
treatment duration, high pill burden, and strong side effects of TB 
medications have been some of the important contributing factors for 
non-adherence to TB treatment in India [6]. 
As of today, pills and injections are the two modes of therapeutic 
treatment available for TB patients. These oral or injectable standard 
anti-TB drug regimens are well established, relatively inexpensive 
therapies, and available free of cost under the government of India’s 
Revised National Tuberculosis Control Program (RNTCP) [4,7]. It is 
evident from the rise of MDR-TB that, new therapeutic approaches may 
be an important avenue to improve adherence to TB medications 
[1,6,8,9]. 
Inhalation therapy, a treatment by inhaling drugs into the respira-
tory tract which includes the nose, pharynx, larynx, trachea, bronchi, 
and alveoli of the lung could potentially be an underexplored avenue to 
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increase TB treatment adherence [1]. Inhalation therapy for TB was 
initially investigated in Russia and there has been a rising interest in this 
new drug delivery technique [10,11]. Inhalation therapy holds promise 
as an alternative route of administration that limits systemic side effects 
and delivers high and localized drug concentrations to the site of action 
[12]. It uses the alveolar-capillary interface to attain satisfactory sys-
temic levels whereas minimizing the risk of systemic toxicity noticed 
with parentally delivered doses [13]. Over the last five decades, many 
different formulation approaches for inhalation have been investigated. 
Micro, nanoparticles, liposomes, proliposomes, and liposphere, with 
single and combination drugs have all been tried but mostly limited to 
data collected in vitro or from preclinical studies where for the majority, 
formulations were found effective in reducing bacterial counts [1,14- 
17]. There have been studies which have used aminoglycosides solution 
administered via nebulization for patients with smear-positive pulmo-
nary TB. This resulted in inhibition of bacillary growth in alveoli, but it 
failed to affect the bacteria inside the macrophages [11]. However, there 
are other studies which have similarly attempted the aerosolized drugs 
like interferon gamma (IFN-g) among smear and culture positive pul-
monary MDR-TB patients and have reported negative smears as well as a 
clear radiological improvement and a reduction in the size of the cavi-
tary lesions [18,19]. This signifies that mere aerosolizing drug may not 
work and for efficient bacteria killing, drugs need to be formulated into 
suitable delivery systems ensuring their rapid uptake into the macro-
phages which harbor the tubercle bacilli [11]. Furthermore, the complex 
host-pathogen relationship and lungs morphology restricts us in 
achieving sufficiently high drug concentration and targeting drug to 
alveolar region. Patient’s age, breathing pattern, optimized formulation 
properties, device performance, and the patient’s understanding/ 
awareness are key to determine the real fate of aerosol and the final 
success of inhaled therapy [13]. 
Inhalation as a drug delivery method could hold to be a key potential 
new drug delivery mode for millions of TB patients. Many biomedicine 
and clinical researchers have hypothesized that inhalation drug delivery 
may reduce treatment times and possibly limit the insurgence of drug 
resistance [10,11,20]. However, before moving towards this innovative 
exploration on alternative therapeutic options in the form of inhalants, it 
is essential to understand patient preferences towards drug delivery 
mechanisms. 
The aim of this study was to assess TB patients’ preferences for 
inhalation therapy over injections/pills and identify its association with 
sociodemographic characteristics (age, gender, and socioeconomic 
class) and clinical characteristics (duration of the treatment, pill burden, 
experience of side-effects, and medication doses interruption). 
2. Materials and methods 
2.1. Ethics statement 
This study was approved by the Institutional Review Board of the 
Penn State College of Medicine, Hershey, Pennsylvania, United States 
(#STUDY00010507). 
2.2. Study design and settings, and participants 
This cross-sectional study was conducted at three Directly Observed 
Treatment Short-course (DOTS) centers in Bhiwandi City (15 miles 
North-east of Mumbai) of Maharashtra state, in Western India. These 
three DOTS centers were located at Shanti Nagar, Gayatri Nagar, and 
Nayi Basti slum areas in Bhiwandi City. The DOTS centers selected for 
this study conduct primary TB prevention activities, including screening 
and outpatient treatment administration services to TB patients in their 
respective catchment areas as identified by their names. Only those 
participants who visited any of the three DOTS centers during the time 
of data collection were recruited in the study. 
2.3. Inclusion and exclusion criteria 
Inclusion Criteria  
• Ability to give the written consent  
• Patients who can understand Hindi Language  
• 18 Years and above  
• Patients diagnosed with pulmonary TB 
Exclusion Criteria  
• Patients registered at any other DOTS center in the area except the 
three selected DOTS centers.  
• Patients who have been undergoing TB treatment for less than one 
month 
2.4. Sampling 
Using the estimated 50% TB medication non-adherence prevalence 
rate in India [21], the sample size of 350 was calculated at 80% power 
and 0.05 level of significance. 
2.5. Measurements 
A survey instrument was designed and was administered to the re-
spondents to identify the preference of inhalants among pulmonary TB 
patients. This survey instrument was translated into Hindi. 
2.5.1. Demographic information 
The sociodemographic information included age, gender, and so-
cioeconomic status. The age was further categorized in three groups 
(18–35 years, 36–49 years, and 50 years & above). Socioeconomic status 
was identified using Kuppuswammy Scale [22]. This scale is a validated 
instrument which uses consumer price index and categorizes the par-
ticipant’s socioeconomic class into three categories (upper, middle, and 
lower). 
2.5.2. Clinical characteristics 
This includes variables such as the duration of TB treatment (up to 1 
year and more than 1 year), number of pills consumed per day (1–4 pills 
per day and 5 or more pills/day), experience of side effects (Yes/No), 
and medication dose interruption. Medication dose interruption and its 
frequency during the last month was identified using two questions of 
the designed survey instrument. The question on medication dose 
interruption and its frequency was categorized in three groups; zero 
missed doses, missed 1–5 doses, and missed 6 or more doses in the last 
one month. The frequency of missing doses was decided based on the 
patterns of interruption among tuberculosis patients [23]. 
2.5.3. Inhalant preference 
The preference of inhalant over pills/injections was measured using 
the question, “Would you prefer inhalants over injections/pills”, with a 
closed response of Yes/No. 
2.6. Data collection 
The study was conducted in two phases. The first phase was con-
ducted in September–October 2018 and 212 surveys were completed 
during the first phase. A total of 265 surveys were completed in the 
second phase which was conducted in September-October 2019. In all a 
total of 477 participants were surveyed. The collected data were self- 
reported and only those participants who visited the three DOTS cen-
ters at the point of data collection were recruited in the study. The study 
respondents received a peanut and dry fruits nutrition bar package, 
irrespective of their decision to participate in the study. Pilot testing of 
the study procedures and the survey were conducted at the different 
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DOTS centers in Bhiwandi city. 
2.7. Statistical analysis 
The data were analyzed using Statistical Package for the Social Sci-
ences (SPSS) version 26, 2018 software [24]. The following analytical 
strategies were employed to examine the preference of inhalants over 
injections/pills. First, descriptive statistics were used to present the 
basic sample characteristics. Second, multivariable logistic regression 
models were applied to identify the association between the preference 
of inhalants over injection/pills and other sociodemographic and clin-
ical variables. The Wald test was used to determine potential associa-
tions at a significance level of p ≤ 0.05. 
3. Results 
Out of 477 study participants, women comprised more than half 
(58%) of the study population. More than two thirds (66%) of the re-
spondents 18–35 years of age. Close to 74% of the study participants 
belonged to the lower socioeconomic class. The majority (62%) of pa-
tients reported a treatment duration of less than one year. More than 
two-thirds (72%) of the respondents took 1–4 pills per day and 68% of 
the patients experienced side-effects of their TB medication. Among all 
study participants, 23% missed their doses in the last month. Among this 
group more than 61% patients missed their doses 1–5 times, and the 
remaining 39% patients missed their doses ≥ 6 times in the last month. 
When asked about the preference of inhalants over pill/injections, 77% 
of the total 477 patients responded, and among them, 23% revealed that 
they would prefer inhalants over injections/pills (Table 1). 
Among the participants who preferred inhalants over injections/ 
pills, the majority (53%) of them were women. More than two-thirds 
(66%) of the respondents who preferred inhalants were in the age 
group of 18–35 years. Around 78% of the respondents who preferred 
inhalants belonged to the low socioeconomic class. The duration of 
treatment among 63% of the patients who preferred inhalants was one 
year or less. The majority (66%) of the patients who preferred inhalants 
consumed 1–4 pills per day compared to the remaining patients who 
consumed 5 or more pills per day. Around 76% of the patients who 
preferred inhalants revealed that they have experienced side-effects 
from taking TB medications. Finally, about 20% of the patients who 
preferred inhalants had had missed at least one dose of TB medication in 
the last month. Among them, 12% patients had missed their doses 1–5 
times and 8% had missed their doses more than 6 times in the last month 
(Table 2). 
After adjusting for age, gender, and socioeconomic class, the pref-
erence of inhalants over pills/injections among pulmonary TB patients 
were significantly associated with duration of TB treatment, number of 
pills taken per day, and reported experience of side-effects from TB 
medications. The TB patients who underwent treatment for more than 
one year were 1.7 times more likely to prefer inhalants over pills/in-
jections (Adjusted OR = 1.684 [95% CI: 1.006–2.818]). Further, pa-
tients taking five or more pills per day were 1.7 times more likely to 
prefer inhalants over injections/pills when compared with patients 
taking 1–4 pills per day (Adjusted OR = 1.681 [95% CI: 1.022–2.763]). 
Patients who had experienced side-effects were two times more likely to 
prefer inhalants over pills/injections (Adjusted OR = 2.008 [95% CI: 
1.185–3.403]) (Table 3). 
Table 1 
Socio-demographic and clinical characteristics pulmonary tuberculosis patients 
(n = 477).  
Socio-demographic and Clinical variables N (%) 
Gender  
Male 199 (41.7) 
Female 278 (58.3) 
Age in years  
18–35 330 (69.2) 
36–49 77 (16.1) 
≥50 70 (14.7) 
Socioeconomic Class  
Lower 361 (75.7) 
Middle 86 (18.0) 
Upper 30 (6.3) 
Duration of the TB Treatment  
Up to 1 year 295 (61.8) 
More than 1 year 140 (29.4) 
Number of Pills Taken Per Day  
1–4 344 (72.1) 
≥5 133 (27.9) 
Have Experienced Side Effects of TB Medications  
Yes 325 (68.1) 
No 146 (30.6) 
Inhalant Preference over pills/inections  
Yes 109 (22.9) 
No 259 (54.3) 
Number of TB Medication Doses Missed in Last One Month  
Never Missed 368 (77.1) 
1–5 times 66 (13.8) 
≥6 times 43 (9.0)  
Table 2 
Sociodemographic and clinical characteristics based on drug delivery prefer-
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259 (54) 368 (77) 






















44 (17.0) 56 (15.2) 
≥50 18 
(16.5) 
35 (13.5) 53 (14.4) 
Socioeconomic Class    





47 (18.1) 68 (18.5) 
Upper 3 (2.7) 21 (8.1) 24 (6.5) 
Duration of the TB Treatment    






More than 1 year 36 
(37.5) 
64 (26.8) 100 
(29.9) 









62 (23.9) 99 (26.9) 
Have Experienced Side Effects of TB 









96 (37.4) 121 
(33.4) 
Number of TB Medication DosesMissed in Last 
One Month    






1–5 times 13 
(11.9) 
42 (16.2) 55 (14.9) 
≥6 times 9 (8.3) 23 (8.9) 32 (8.7)  
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4. Discussion 
Several studies examining preferences among various routes of drug 
delivery for chronic diseases typically yielded findings in the expected 
direction with easier or more convenient routes of administration 
preferred over more difficult routes of administration [25-31]. There 
have been studies conducted among patients with osteoporosis, diabetes 
and multiple sclerosis where respondents were found to prefer oral over 
injectable administration [26-28], and inhaled medication over in-
jections [29,30]. Some studies have also shown preference for pills over 
inhaled medication and injections [30,31]. However, there is a scarcity 
of literature on the treatment preferences for the various routes of 
administration of TB treatment. The present study focused on largely 
unexplored issue, that is, the TB patient’s preference of the use of in-
halants over injections/pills as a choice of drug delivery method. Many 
of the patients have the experience of using pills and injections for TB 
treatment, however this study gave an opportunity for the TB patients to 
give their hypothetic preference without direct experience of using in-
halants for their TB treatment. The study results revealed that, inhalant 
preference over pills/injections had a significant association with clin-
ical variables like long treatment duration, high pill burden, and re-
ported side-effects of TB medications. 
A fundamental problem that hinders more effective TB control is the 
ability of TB bacteria to persist in the host and to develop drug resis-
tance, often because of poor adherence to lengthy therapy [32]. While 
there are several clinical trials which are looking at shorter drug regi-
mens, most of the new agents identified as anti-TB drug candidates are 
still in the preclinical phases [32]. Rather than focusing on treatment 
agents, this study guides us towards inhalants as a potential preference 
of drug delivery method among some pulmonary TB patients. Patients 
with a longer treatment duration (more than 1 year) have shown more 
interest towards inhalation therapy in this study. Hence, while it is 
important to focus on new anti-TB drug candidates, it becomes equally 
imperative to think simultaneously towards utilizing alternative 
methods of drug delivery. These drug delivery methods could poten-
tially improve TB medication adherence for the patients with MDR-TB in 
India where the standardized treatment regimen is a 6-drug regimen, 
with an intensive phase of 6–9 months and a continuation phase of 18 
months; for a total treatment duration of about 24–27 months [33]. 
Another important barrier to TB-medication adherence for TB pa-
tients is pill burden. A MDR-TB patient swallows about 14,600 pills in 
two years of treatment and undergoes 8 months of painful injections 
[34]. Burden of such a huge number of pills also affects patient adher-
ence and influences health seeking behavior, with adherence rates 
dropping to as low as 20% among patients who must take thirteen or 
more pills each day [35]. In our study, the preference for inhalants was 
found to be more common among the patients who consumed five or 
more pills per day. Hence, innovative drug delivery methods which 
could reduce their pill burden and contribute towards effective 
compliance. 
In addition to the pill burden, side-effects are another cause of 
concern associated with TB treatment. Harsh side effects contribute to-
wards non-adherence and are potential reasons towards the develop-
ment of MDR-TB [6,8,36]. Injectable agents on the other hand, have 
been found to be among the most problematic medications in use, cause 
a great deal of pain and distress for patients, and are associated with 
frequent, serious adverse effects [37]. This study further strengthens this 
argument as patients experiencing some form of side effects from TB 
medications were found to be more likely to prefer inhalants over pills/ 
injections. 
Overall, duration of treatment, pill burden and painful side effects of 
TB medications/injections leads to intentional nonadherence where 
patients might skip their doses or cut their number of pills without 
informing their provider [38]. Considering these challenges associated 
with pills and injections, it becomes imperative to think of future 
research strategies regarding the development and design of new drug 
delivery methods for TB patients. Inhalation therapy could be one such 
method which needs further exploration. 
A major therapeutic advance took place in 1997, when tobramycin 
designed for inhalation was approved by the U.S. Food and Drug 
Administration (FDA) for use in patients with cystic fibrosis (CF) with 
chronic Pseudomonas aeruginosa infection [14]. Attracted by the clin-
ical benefits observed in CF, there has been a growing interest in the use 
of inhaled antibiotics in other lower respiratory tract infections, such as 
TB [1]. However, there are also existing practical barriers associated 
with the usage of inhalers. These barriers include forgetfulness and poor 
routines, inadequate inhaler technique, organizational difficulties (such 
as repeat prescriptions), and families not understanding or accepting the 
use of an inhaler [39]. There are families and people in India who 
believe that that inhalers could stigmatize individuals and also poten-
tially become a habit among patients with chronic conditions [40,41]. 
Additionally, other challenges remain: for instance, the use of special-
ized delivery devices could, perhaps, make this therapeutic avenue more 
expensive then oral delivery, resulting in a disadvantage for imple-
menting this therapy on a large scale, especially in developing countries 
like India [1]. Hence, pills and injections should remain available 
alongside inhalants. 
5. Study limitations 
The sample size was small, and data were collected from just three 
DOTS centers in Mumbai, therefore the results may not be generalized to 
all pulmonary tuberculosis patients. The other limitation of the study is 
that the main outcome question about inhalant preference does not 
differentiate between injections and pill taking preferences. In addition, 
the study had participants with a treatment duration ranging from 6 
months to 2 years and did not distinguish between resistant and non- 
Table 3 
Association of inhalant preference over pills/injections and clinical character-













Duration of the TB 
Treatment     
Up to 1 year Referent  – Referent  – 





Number of Pills Taken 
Per Day     






Have Experienced Side 
Effects of TB 






No Referent  – Referent  – 
Number of TB 
Medication Doses 
missed in the last 
month     
Never Missed Referent  – Referent  – 










OR, Odds ratio; CI, confidence interval; variables- gender, age in years, and 
socioeconomic class were adjusted in determining the association of inhalant 
preference with each of the clinical variables (duration of TB treatment, number 
of pills taken per day, experiencing side-effects and number of TB medication 
doses missed in last one month); p ≤ 0.05 statistically significant. 
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resistant patients. Hence, the results cannot be generalized to a partic-
ular group of TB patients or to a particular preference for injections or 
pills. Future research with specific groups of patients and one with 
differentiating injections and pill taking preferences might be useful. 
Another limitation of the study was, the inhalant preference question 
was given as yes/no question but only 77% of patients responded to that 
question and 23% of them did not answer the main outcome question. 
There might be a possibility where they did not know the answer, 
however the question did not give them the liberty of an option to say 
that they did not know. Future studies must consider incorporating the 
did not know response so that it can help identify the reasons for missing 
cases. Lastly, the study relied on self-report during interviews given by 
field staff, and we were not able to map it with the e-nikshay system for 
confirmation. This could result in recall or respondent bias. 
6. Conclusion 
The study results signify that inhalants could be an acceptable 
method of drug delivery in this population of TB patients. In this study, 
the preference of inhalants was significantly associated with clinical 
factors like treatment duration, pill burden and experience of side effects 
from TB medication. While the world remains committed to tackling TB 
through early detection and limiting the exposure among non-infected 
individuals; there is still a need to invest more in research, including 
basic and applied TB research and the development of shorter innova-
tive therapies and new modes of drug delivery methods which could 
potentially improve adherence. Although the study results reported 
participants preferring inhalants over pills/injections, future research 
should examine the reasons associated with these choices along with 
other alternatives like syrups or a combination of all these choices (pills, 
injections, inhalants, and syrups) of drug delivery methods could be 
considered. Furthermore, in the future, it would be worthy to explore 
and compare the inhalation preferences among diverse group of TB 
patients such as 1) pediatric cases, 2) pulmonary TB patients, 3) 
extrapulmonary cases, 4) MDR-TB patients, 5) Pre-XDR TB patients, and 
6) XDR-TB patients. In addition, it would also be beneficial to explore 
the distinction in preferences of inhalants between drug resistant and 
non-drug resistant TB patients. Overall, these studies may eventually 
contribute towards understanding the generalization of inhalant pref-
erences among diverse group of TB patients. 
Finally, considering the complexities of TB treatment including 
treatment duration, pill burden, multi-drug resistance, side-effects and 
other socioeconomic determinants around TB, there cannot be a one size 
fits all solution for the treatment delivery options of a complex disease 
like TB. Diverse drug delivery options for TB patients may greatly in-
crease TB-medication adherence. 
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